NCT02972255View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 24, 2017

Study Completion Date

March 24, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

RO7079901

RO7079901 will be administered as per schedule described in individual arm.

DRUG

Meropenem

Meropenem will be administered as per schedule described in individual arm.

OTHER

RO7049389 Placebo

Placebo matching to RO7049389 will be administered as per schedule described in individual arm.

OTHER

Meropenem Placebo

Placebo matching to meropenem will be administered as per schedule described in individual arm.

Trial Locations (2)

47710

Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville

53704

Covance Clinical Research Unit, Inc, Madison

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02972255 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers | Biotech Hunter | Biotech Hunter